CD19-specific CAR-T Cells in CLL/SLL, DLBCL and ALL
Phase I, Open Label, Multicenter, Dose Escalation Study of YTB323 in Adult Patients With CLL/SLL, DLBCL and ALL
ClinicalTrials.gov Identifier: NCT03960840
Novartis Reference Number: CYTB323A12101
Last Update: Jan 17, 2023
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of YTB323. YTB323 will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (DLBCL) and in adult acute lymphoblastic leukemia (ALL).
Interventions
Eligibility Criteria
Inclusion Criteria:
ECOG performance status 0-1
CLL or SLL diagnosis according to iwCLL criteria
CLL/SLL in SD or PR after at least 6 months of ibrutinib, either as second or subsequent line of therapy
DLBCL diagnosis by local histopathology
DLBCL relapsed or refractory after 2 or more lines of therapy, including autologous hematopoietic stem cell transplantation (HSCT)
Refractory or relapsed CD19-positive ALL
ALL with morphologic disease in the bone marrow
Exclusion Criteria:
Prior CD19-directed therapy
Prior administration of a genetically engineered cellular product
Prior allogeneic HSCT
Richter's transformation
Active CNS lymphoma
Targeted small molecule or kinase inhibitor within 2 weeks from leukapheresis
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]